End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.63 MXN | +1.77% | +4.73% | -0.08% |
Apr. 24 | Transcript : ALPEK, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 24, 2024 | |
Apr. 23 | ALPEK, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The stock, which is currently worth 2024 to 0.39 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.08% | 1.57B | B+ | ||
-8.99% | 4.55B | C- | ||
-2.51% | 3.6B | C | ||
+2.63% | 2.16B | - | - | |
-14.63% | 1.25B | B | ||
-9.05% | 978M | - | D+ | |
-7.02% | 927M | - | ||
-5.37% | 588M | - | - | |
-25.35% | 453M | - | ||
-15.38% | 395M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALPEK A Stock
- Ratings ALPEK, S.A.B. de C.V.